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Abstract: Progesterone and allopregnanolone have crucial 
and different roles in brain development, function and 
recovery after injury. Pregnancy is characterized by an 
increased synthesis of progesterone and its neuro-active 
metabolites by the placenta, maternal and fetal brain. 
This supports the critical role of these steroids in mater-
nal brain adaptation during pregnancy and development 
of the fetal brain. Moreover, allopregnanolone may play a 
brain-protective role during complications of pregnancy, 
complications of pregnancy, such as preterm delivery or 
intrauterine growth restriction (IUGR), by reducing the 
impact of hypoxia and excitotoxic brain damage or impair-
ment myelination. Behavioral consequences of altered 
progesterone/allopregnanolone fetal brain programming 
have also been hypothesized, although further evidence is 
needed. New potential applications of allopregnanolone 
as a treatment strategy have also been proposed, address-
ing unmet clinical needs in perinatal care.
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Introduction
The brain is a target and a source of progesterone synthesis 
and action. The synthesis of progesterone in the nervous 
system has been demonstrated in several species and the 
enzymes required for progesterone and allopregnanolone 
synthesis are widely distributed throughout the brain and 
spinal cord. The behavioral and neuroprotective effects 
of progesterone and allopregnanolone have been widely 
recognized in traumatic brain injury, ischemic stroke and 
neurodegenerative disease, at least in in vitro and in vivo 
studies [1].
Multiple receptors or associated proteins may contrib-
ute to the progesterone effects: classical nuclear recep-
tors (PRs), membrane progesterone receptor component 
1 (PGRMC1), membrane progesterone receptors (mPRs), 
and γ-aminobutyric acid type A (GABAA) receptors after 
conversion to allopregnanolone.
Progesterone and allopregnanolone are the most 
important neuroactive steroids during pregnancy, as 
they are found in remarkably high concentrations in 
the fetal and maternal circulation and brain. Increased 
local biosynthesis of pregnenolone, progesterone and 
5α-dihydroprogesterone may be a part of an endogenous 
adaptive mechanism in maternal and fetal brain during 
pregnancy [2].
Here, we describe the potential mechanisms involved 
in the action of progesterone (and its metabolite, allopreg-
nanolone) in the brain during pregnancy.
Mechanism of actions of 
 progesterone in the brain
A comprehensive account of the molecular and cellular 
activities of progesterone on the central nervous system 
(CNS) is beyond the scope of this article, and several 
recent reviews of the subject are available [1, 3]. However, 
in an attempt to describe the biological plausibility of 
the hypotheses that progesterone and progestins greatly 
affect brain function, the mechanisms that seem most rel-
evant will be briefly described here.
The different physiological effects of progesterone 
can be mediated by both PRs and membrane receptors [4].
The most common isoforms of PRs are PR-A and PR-B, 
which are responsible for the transcriptional effects of 
progesterone. Although both PRs are generated from a 
single gene [5], PR-B differs from PR-A by an additional 
164 amino acid sequence in the N-terminal region [6]; thus 
the different structure gives them diverse transactivational 
properties observed both in vitro [7, 8] and in vivo [9, 10]. 
Interestingly, a third isoform, PR-C, has also been iden-
tified, which is thought to modulate the transcriptional 
activity of PR-A and PR-B [11, 12]. The differential struc-
ture of the PR isoforms confers distinct tissue-specific 
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responses to progesterone, through post-translational 
modifications, dimerization and recruitment of cofactor 
proteins contributing to the differential transactivation 
properties of each isoform. Consequently, these events 
lead to the regulation of distinct substrates of progester-
one-dependent target genes [3].
In the CNS, PR-A and PR-B were identified, although 
their biological properties are not yet completely defined 
[13–15]; instead, there is no evidence for the existence of 
PR-C isoform to date [3]. Reverse transcription-polymerase 
chain reaction (RT-PCR) analyses revealed the expression 
of both the PR-A and PR-B mRNA transcripts in all regions 
of the brain where the neural PRs are known to be present 
[3]. Their co-localization in several brain districts such as 
amygdala, hippocampus, cortex, basal forebrain, cerebel-
lum, locus coeruleus, midbrain rafe nuclei, glial cells and 
gray matter could confirm the involvement of progester-
one in the control of well-being, cognitive functions and 
memory processes in physiological as well as pathologi-
cal conditions [16]. Furthermore, in the adult female rat 
brain, estradiol (E2) and progesterone differentially regu-
late the isoforms in distinct regions of the brain [17]. In the 
hypothalamus, estrogen can up-regulate PR-A and PR-B 
expression as PRs are expressed in the same areas of the 
estrogen receptors, while progesterone itself down-regu-
lates them. In the hippocampus, only PR-A expression is 
up-regulated by E2, while progesterone has no influence 
in both PR expressions [17]. However, in the cerebellum 
and the frontal cortex, neither E2 nor progesterone has 
any effect on PR isoforms’ mRNA expression. Moreover, 
the transcription of PR isoforms varies with the estrous 
cycle in a region-specific manner; for example, studies 
on E2-treated rhesus macaques indicate a region-specific 
regulation of the PR isoforms, with PR-B expression being 
predominant in the hypothalamus and PR-A in the pitui-
tary [18, 19].
The increasing in vitro and in vivo evidence of dif-
ferential transcriptional activities and co-regulator inter-
actions between PR-A and PR-B predict that these two 
isoforms could have distinct roles in mediating additional 
and/or alternate signaling pathways within steroid- 
sensitive neurons [3]. In addition, genetic variations of 
the common progesterone receptor gene described in the 
endometrium and the breast tissue might be associated 
with functional differences inside the brain. Similarly, 
an association between receptor transcriptional silenc-
ing and the methylation status of PR-A and PR-B promoter 
regions is well documented, and hypermethylation of PR-B 
induces a down-regulation of the receptor [20]. However, 
no data is currently available for the methylation status of 
brain PR-A and PR-B. In ongoing clinical trials, premature 
infants have been treated with a continuous infusion of 
P and estradiol for the initial few weeks of life: prema-
ture infants treated with hormones achieved normal psy-
chomotor development earlier than untreated premature 
infants [21].
Concerning non-classical pathways, several studies 
have demonstrated that progesterone is able to interact 
with membrane receptors such as the PGRMC1, s1 recep-
tor and GABAA receptor, through allopregnanolone; 
PGRMC1 is localized on the membrane of hypothalamic 
and spinal neurons [22, 23] and its expression was shown 
to be induced by E2 treatment, thus suggesting a role in 
the activation of female sex behavior [22]. Moreover, a role 
of PGRMC1 in mediating protective effects of progesterone 
in the nervous system is also supported by the observa-
tion that its mRNA and protein were up-regulated by 
progesterone treatment in dorsal horn neurons of spinal 
cord-injured male rats [23]. Another membrane receptor 
of progesterone is the s1 receptor that is involved in the 
neuronal aging processes [24, 25]. The receptor is involved 
in the potentiation of the N-methyl-D-aspartate (NMDA) 
response of hippocampal neurons and the NMDA-evoked 
norepinephrine release but the presence of progesterone 
leads to a reduction of s1 activity [26, 27].
Furthermore, progesterone plays a role in the control 
of other transmission systems like opioidergic, serotonin-
ergic and cholinergic. The nicotinic receptor of acetylcho-
line is a target of progesterone as well, and progesterone 
inhibits the activity of the receptor independently of the 
membrane potential [28, 29].
Studies in vitro have shown that PR, like other steroid 
receptors, can be modulated by compounds other than 
steroids in a “ligand-independent manner”. These mole-
cules include cyclic nucleotides that increase intracellular 
kinase activity [30], as well as extracellular compounds 
that interact with membrane receptors and stimulate 
intracellular phosphorylation pathways, including growth 
factors and neurotransmitters like dopamine.
Thus, the “ligand-dependent” (genomical/ classical 
and non-genomical/non-classical) and the ligand- 
independent mechanisms of PRs activation and sensi-
tization allow steroids to widely affect the regulation of 
cerebral activities.
Allopregnanolone synthesis
Neurons and glia cells possess all the enzymes neces-
sary for progesterone, testosterone and estradiol metabo-
lism [aromatase, 5α-reductase (5α-R) mainly in neurons, 
(3α-hydroxysteroid dehydrogenase, 3α-HSD) mainly 
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in type 1 astocytes]. Allopregnanolone (3-hydroxy-5- 
pregnan-20-1), is a 3,5-reduced metabolite of progesterone 
produced by the enzyme 5α-R and 3α-HSD. Allopregna-
nolone is a neurosteroid produced by the CNS, adrenals 
and ovaries [11]. Allopregnanolone is a potent endogenous 
steroid that rapidly affects the excitability of neurons and 
glial cells through direct modulation of GABAA receptor 
activity [12, 13]. In addition, allopregnanolone exhib-
its neurotrophic/neuroprotective actions, reducing cell 
death, gliosis, and functional deficits after traumatic 
brain injury in rats and in experimental models of Alzhei-
mer’s disease [14]. Experimental data suggested a direct 
functional association between allopregnanolone brain 
content, neurosteroids and sex steroid concentration in 
experimental models of ovarian function withdrawal.
Effects of progesterone and allopreg­
nanolone in the developmental brain
The critical role of progesterone in brain activity has been 
postulated as evidence that Purkinje cells (a typical cer-
ebellar neuron) have been shown to express P450scc and 
3β-HSD during postnatal development and in adulthood, 
and were demonstrated to be a source of progesterone and 
allopregnanolone particularly during the neonatal period 
when enzymatic activities increase [31].
Progesterone may also affect oligodendrocyte dif-
ferentiation. Oligodendrocytes and their precursors dif-
ferentially express enzymes needed for progesterone and 
other neurosteroid production, suggesting that these com-
pounds may be involved in oligodendrocyte progenitor 
proliferation and differentiation during development [32]. 
Oligodendrocyte pre-progenitors, precursors, and fully 
differentiated oligodendrocytes differentially express 
3β-HSD, 5α reductase and 3α-HSD. Pre-progenitors have 
highest expression of 3β-HSD and 3α-HSD, and can 
convert pregnenolone to progesterone. 3α-HSD activity 
is highest in oligodendrocyte pre-progenitors, but is also 
found in oligodendrocyte precursors and mature oligo-
dendrocytes. In contrast, mature oligodendrocytes have 
the highest levels of expression of 5α-reductase but are 
unable to convert pregnenolone to progesterone, suggest-
ing a lack of 3β-HSD expression [32, 33].
Progesterone also stimulates myelination in the CNS 
[33, 34]. In slice cultures of 7-day-old rat and mouse cer-
ebella, high concentrations of progesterone (20–50 μM) 
increased expression of myelin basic protein about four-
fold. This effect may be mediated through progesterone 
receptors as the selective progesterone receptor agonist 
R5020 also increased expression of myelin basic protein 
while the progesterone receptor antagonist RU-486 abol-
ished the effect of progesterone. The involvement of the 
progesterone receptor was confirmed using cerebellar 
slice cultures from progesterone receptor knockout mice. 
In those animals, progesterone had no significant effect 
on myelin basic protein expression. In addition to direct 
effects of progesterone on its nuclear receptor, some 
effects on expression of myelin basic protein were likely 
mediated through neurosteroid metabolites of progester-
one (allopregnanolone). A 5α-reductase inhibitor partially 
inhibited the effect of progesterone, and allopregnanolone 
significantly increased expression of myelin basic protein, 
although this stimulation was less than that found with 
progesterone treatment. In addition, the GABAA receptor 
antagonist bicuculline inhibited the effect of allopregna-
nolone on increasing expression of myelin basic protein. 
Thus, progesterone affects myelination not only in the 
peripheral nervous system but also in the CNS as well 
through mechanisms that involve both the progesterone 
receptor and the GABAA receptor [35].
The role of progesterone and 
 allopregnanolone in fetal brain
Progesterone and allopregnanolone are the most impor-
tant neuroactive steroids during pregnancy, as they are 
found in remarkably high concentrations in the fetal 
circulation and brain [36, 37]. Besides contributing to 
the maintenance of pregnancy, these hormones are also 
important to facilitate adaptations of maternal brain 
needed for timely parturition, lactation and for expression 
of appropriate maternal behavior postpartum [36, 37]. 
During gestation, increased levels of allopregnanolone 
are observed both in maternal and fetal circulation [38]. 
This could probably be explained by the fact that the 
maternal brain has an increased capacity to generate neu-
rosteroids during pregnancy [38]. Neurosteroid levels drop 
quickly after birth and this event may reduce neuroprotec-
tion and cause some problems for preterm newborns [39]. 
Studies carried out on sheep have shown that allopregna-
nolone levels in the fetal brain are increased during gesta-
tion, particularly near term [36, 39]. Moreover, it has also 
been shown that the GABAA receptor is expressed in fetal 
sheep brain and its expression rises with advancing ges-
tation [2, 40]. Several research works indicate that some 
interactions between placenta and brain, due to increas-
ing expression of 5α-reductase in these two organs, may 
regulate concentrations of allopregnanolone in the fetal 
and maternal brain [40]. 5α-Reductase activity may be the 
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major determinant of the levels of neuroactive steroids 
found locally within regions of the brain. Total activity 
may be a product of the activities of the two 5α-reductase 
isoforms, type-1 and type-2. Both isoforms are expressed 
in fetal sheep and guinea pig brains throughout late 
gestation.
We previously demonstrated that estetrol, E4, a nat-
urally occurring estrogen only produced by the human 
fetal liver, increased allopregnanolone levels in the brain 
and in the circulation, underlying the crucial role of allo-
pregnanolone during human fetal brain development [41] 
(Figure 1).
Recent findings suggest that the neurosteroid milieu 
deeply influences behavioral state and exerts a tonic 
suppression of CNS excitability in the fetus [42]. This is 
supported by findings that the inhibition of neuroactive 
steroid synthesis during pregnancy, either by lowering 
placental progesterone synthesis, using a 3β-HSD inhibi-
tor, or blocking the metabolism of progesterone to allo-
pregnanolone, markedly increases arousal-like behavior 
and excitation in the ovine fetus. Furthermore, this indi-
cates that allopregnanolone levels markedly influence 
behavioral states during fetal life and may have a major 
impact on brain development. The hypothesis according 
to which the fetal brain itself plays a key role in regulating 
levels of allopregnanolone is supported by the evidence 
that its concentrations in the fetal brain rise further after 
hypoxic stress [40, 42].
There is now increasing evidence that neurosteroids 
improve outcomes following hypoxic/ischemic brain 
injury in adults by aiding tissue repair. These processes 
involve increased production of allopregnanolone and 
its interaction with GABAA receptors. Suppression of 
allopregnanolone production alone increases apoptotic 
cell numbers in the fetal brain in the absence of any inju-
rious process. Reduced allopregnanolone levels nega-
tively affect the number of brain cells. These effects of 
inhibiting neuroactive steroid synthesis were blocked 
by the co-infusion of alfaxalone, suggesting that allo-
pregnanolone in the fetal brain is required to maintain 
constitutive levels of cell death and proliferation in late 
development.
Previous findings show that neuroactive steroids 
stimulate myelination, an action thought to involve neu-
roactive steroid-induced stimulation of GABAA receptors, 
which appears to indirectly affect oligodendrocytes. This 
idea is supported by a recent study where recovery from 
acute perinatal hypoxic injury involved increased prolifer-
ation of oligodendrocyte progenitor cells and their matu-
ration into mature oligodendrocytes [35].
Allopregnanolone responses to chronic placental 
insufficiency are mediated by an increase of 5α-reductase 
expression in the placenta and brain, especially in the 
hippocampus [40]. Changes in brain allopregnanolone 
levels seem to be observed also after birth in lambs [36]. 
After exposure to hypoxia, these newborn animals show 
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Figure 1: Multi-level synthesis of allopregnanolone in the maternal-placental-fetal system during human pregnancy.
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a rise in brain allopregnanolone concentrations [2, 36] 
and plasma cortisol [2]. These observations suggest that 
allopregnanolone may also play a neuroprotective role in 
newborns, not only during gestation [2].
Conclusions
Progesterone and allopregnanolone have crucial and 
somewhat different roles in brain development, function 
and recovery after injury. Pregnancy is characterized by 
an increased synthesis of progesterone and its neuro-
active metabolites by the placenta, and the maternal and 
fetal brain. This supports the critical role of these ster-
oids in maternal brain adaptation during pregnancy and 
development of fetal brain. Moreover, allopregnanolone 
may play a brain-protective role during complications 
of pregnancy, such as preterm delivery or intrauterine 
growth restriction (IUGR), reducing the impact of hypoxia 
and excitotoxic brain damage or impairment myelination. 
Behavioral consequences of altered progesterone/allo-
pregnanolone fetal brain programming have also been 
hypothesized, although further evidence is needed. New 
potential applications of allopregnanolone as a treatment 
strategy have been proposed, addressing unmet clinical 
needs in perinatal care.
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